441 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457 http://www.zacks.com/stock/news/374236/inovio-earns-3rd-milestone-fee-from-astrazeneca-for-medi0457?cid=CS-ZC-FT-374236 Apr 09, 2019 - Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men http://www.zacks.com/stock/news/371759/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371759 Apr 06, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371728 Apr 05, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer http://www.zacks.com/stock/news/370142/clovis-posts-data-on-rubraca-study-for-pancreatic-cancer?cid=CS-ZC-FT-370142 Apr 03, 2019 - Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336 Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data http://www.zacks.com/stock/news/369278/advaxis-up-on-positive-early-stage-immunotherapy-study-data?cid=CS-ZC-FT-369278 Apr 02, 2019 - Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA http://www.zacks.com/stock/news/367531/aveo-pharmaceuticals-aveo-to-file-nda-for-fotivda-with-fda?cid=CS-ZC-FT-367531 Mar 29, 2019 - AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-ZC-FT-367176 Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes http://www.zacks.com/stock/news/366338/astrazenecas-forxiga-gets-nod-in-japan-for-type-i-diabetes?cid=CS-ZC-FT-366338 Mar 28, 2019 - AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

Pages: 123456789...45

<<<Page 4>